Compare Cincinnati Financial Corporation (CINF) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Charles River Laboratories Intl. Inc — how do they compare? Cincinnati Financial Corporation trades at $172.86 (market cap $26.58B), while Charles River Laboratories Intl. Inc trades at $285.14 (market cap $13.46B). The key difference: Cincinnati Financial Corporation is the larger of the two by market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CINF | CRL | |
|---|---|---|
Market Cap | $26.58B | $13.46B |
Sector | Financials | Health |
52-Week High | $192.03 | $282.00 |
52-Week Low | $149.79 | $145.57 |
Enterprise Value | $25.71B | $16.30B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $173.86, down 1.7% on the day, with a bearish technical signal and key support at $172. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing revenue growth. Strong fundamentals include a low P/E of 8.18, robust ROE of 21.48%, and a consistent dividend history, with a recent H1-26 dividend of $0.94 declared.
The outlook is cautiously optimistic, supported by a consensus price target of $195 and a 'Moderate Buy' analyst rating. Risks include catastrophe losses impacting underwriting and competitive pressures in commercial lines. Positive cash flow trends and rising investment income provide a solid foundation for long-term growth.
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
